Quarterly information report as at the end of September 2025 Continued solid sales growth in the third quarter(+10% at constant exchange rates and +5% at current exchange rates) Paris, 22 October 2025 In the third quarter, sales continued to grow and reached €3.9 billion, up 10% at constant exchange rates, a slight improvement compared to the second quarter, particularly in Europe, the Americas and Asia. The group’s consolidated revenue amounted to €11.9 billion at the end of September 2025, up 9% at const ...

Core Financial Performance - The bank reported core earnings of DKK 2,321 million and a net profit of DKK 1,753 million for the first three quarters of 2025, reflecting a 21% annual return on equity [1][4] - Total core income for the first three quarters of 2025 was DKK 3,073 million, slightly higher than the same period in 2024 [4] - Earnings per share increased by 4% to DKK 71.2 for the first three quarters of 2025 [4] Expense Management - Total expenses and depreciation amounted to DKK 534 million, a decrease from DKK 761 million in the same period of 2024 [2] - The cost/income ratio improved to 25.6%, indicating effective cost management despite a 4% increase in costs [4] Credit Quality and Impairment Charges - The bank maintained strong credit quality, with impairment charges of DKK 11 million recorded in the quarter, leading to total impairment charges of DKK 35 million for the first three quarters of 2025 [4] - Impairment charges for loans showed a positive trend, with a charge of +24 million in the first three quarters of 2025 compared to +2 million in 2024 [2] Customer Growth and Loan/Deposit Trends - The bank experienced a satisfactory increase in customer numbers, with loans growing at a rate of 7% per annum and deposits at 9% per annum [4]

Core Points - Sampo plc has conducted a share buyback on 21 October 2025, acquiring a total of 351,896 A shares at an average price of EUR 9.66 per share [1][2] - The share buyback program, announced on 6 August 2025, has a maximum limit of EUR 200 million and is in compliance with the Market Abuse Regulation [1] - Following the transactions, Sampo plc now holds a total of 18,131,091 A shares, which represents 0.67% of the total shares outstanding [2] Summary by Sections Share Buyback Details - On 21 October 2025, Sampo plc acquired 351,896 A shares across various markets, with the daily weighted average price being EUR 9.66 [1] - The buyback was executed on multiple exchanges, including AQEU, CEUX, TQEX, and XHEL [1] Program Announcement - The share buyback program was initiated on 7 August 2025, following authorization from Sampo's Annual General Meeting held on 23 April 2025 [1] - The program aims to utilize up to EUR 200 million for the buyback of shares [1] Ownership Post-Transaction - After the buyback transactions, Sampo plc's total ownership of A shares stands at 18,131,091, equating to 0.67% of the total shares [2]

Core Insights - Novartis announced that Cosentyx® (secukinumab) achieved significant results in the Phase III REPLENISH trial for treating polymyalgia rheumatica (PMR), meeting both primary and secondary endpoints [1][7] - The trial demonstrated that Cosentyx provided sustained remission compared to placebo at Week 52, indicating its potential as a novel treatment option for PMR [1][7] Company Overview - Novartis is an innovative medicines company focused on improving and extending patients' lives through advanced therapies, reaching nearly 300 million people globally [9] Product Information - Cosentyx is a fully human biologic that inhibits interleukin-17A, a key cytokine in various immune-mediated inflammatory diseases, and is already approved for multiple conditions including psoriatic arthritis and ankylosing spondylitis [4] - Since its launch in 2015, Cosentyx has treated over 1.8 million patients worldwide and is approved in more than 100 countries [4] Clinical Trial Details - The REPLENISH trial was a global Phase III, multicenter, randomized, double-blind, placebo-controlled study conducted in 27 countries, assessing the efficacy and safety of Cosentyx in PMR patients [3] - The primary endpoint was to determine if secukinumab 300mg plus a steroid taper was superior to placebo plus a steroid taper in achieving sustained remission at Week 52 [3] Disease Context - Polymyalgia rheumatica is the second most common inflammatory rheumatic disease in adults aged 50 and older, characterized by significant pain and stiffness, which can severely impact quality of life [5] - Long-term steroid use, the standard treatment, poses risks such as osteoporosis and diabetes, highlighting the need for effective alternatives like Cosentyx [5]

Core Points - EfTEN Capital AS announced a cash distribution of 16,900 euro cents per unit, totaling 419,772 euros, which represents approximately 2% of the fund's latest closing price [1] - In 2025, the EfTEN United Property Fund has distributed over 9% of its market cap, with total distributions amounting to 1.4 euros per unit since its listing in May 2022 [2] - The distribution is derived from income generated by the EfTEN Real Estate Fund 5, EfTEN Special Opportunities Fund, and owner loan interests from Invego Uus-Järveküla OÜ [3] Distribution Details - The record date for unitholders eligible for the distribution is set for October 31, 2025, with the ex-date being October 30, 2025 [4] - The cash distribution will be executed on November 14, 2025, and will be transferred to unitholders' bank accounts, subject to taxation [5]

Core Insights - Ipsen has reported strong sales growth for the year-to-date and third quarter of 2025, with total sales reaching €2,734.8 million, a 9.6% increase compared to the same period in 2024 [2][7] - The company has upgraded its full-year financial guidance, anticipating total sales growth of around 10.0% at constant exchange rates (CER), up from previous guidance of greater than 7.0% [4][8] Sales Performance - Oncology sales increased by 4.5% year-to-date, reaching €1,912.0 million, while third-quarter sales were €624.0 million, up 3.3% [2] - Rare Disease sales saw a significant rise of 97.0% year-to-date, totaling €255.4 million, with third-quarter sales of €102.0 million, reflecting a 100.8% increase [2] - Neuroscience sales grew by 5.8% year-to-date to €567.3 million, with third-quarter sales of €188.9 million, up 3.9% [2] Pipeline and Acquisitions - Ipsen announced positive data from the Phase II LANTIC trial for IPN10200, a long-acting molecule in aesthetics, and plans to present this data at a scientific conference in H1 2026 [3][5] - The company has proposed the acquisition of ImCheck Therapeutics, which will enhance its oncology pipeline with a first-in-class asset [9][10] Regulatory Approvals - Ipsen received regulatory approval for Bylvay® in Japan for treating pruritus associated with progressive familial intrahepatic cholestasis (PFIC) [6] - The company also obtained European Commission approval for Cabometyx® in advanced neuroendocrine tumors [6] Financial Guidance - The updated financial guidance includes a core operating margin of around 35.0% of total sales, an increase from prior guidance of greater than 32.0% [8] - The company expects an adverse impact of around 3% on total sales from currency fluctuations based on September 2025 exchange rates [8][18]

Merger of equals to create new global critical minerals champion and unlock substantial valueVANCOUVER, British Columbia, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) (Teck) today announced its unaudited third quarter results for 2025. "The merger of equals between Teck and Anglo American announced this quarter is a unique opportunity to create a global leader in critical minerals and a top five copper producer," said Jonathan Price, President and CEO. "The c ...

Core Insights - Borregaard's operating revenues for Q3 2025 were NOK 1,799 million, a decrease from NOK 1,949 million in Q3 2024 [1] - EBITDA fell to NOK 440 million from NOK 524 million year-over-year [1] - Profit before tax decreased to NOK 247 million from NOK 326 million, and earnings per share dropped to NOK 1.96 from NOK 2.51 [3] Revenue and Performance Analysis - The decline in EBITDA was attributed to lower bioethanol prices and a temporary disruption in cellulose production at the Sarpsborg site, which had an estimated negative impact of NOK 40 million [2] - BioSolutions experienced growth in sales to agriculture, contributing positively to the overall results [2] - In BioMaterials, higher sales prices were offset by lower sales volume, while Fine Chemicals showed strong performance [2] Management Commentary - The CEO, Tom Erik Foss-Jacobsen, expressed satisfaction with the strong agricultural sales and the company's ability to deliver solid results amid uncertain global conditions, highlighting the strength and flexibility of Borregaard's business model [3]

By the end of the Q3 2025, Coop Pank had 222,000 customers, increased by 4,000 customers in the quarter (+2%) and by 20,000 in the year (+10%). The bank had 105,400 active customers, increased by 1,800 (+2%) in the quarter and by 10,000 (+10%) in the year. In Q3 2025, volume of deposits in Coop Pank increased by 105 million euros (+6%), reaching total of 1.91 billion euros. Deposits from private customers increased by 9 million euros: demand deposits remained at the same level compared to the previous quar ...

Core Insights - BAWAG Group reported a strong operating performance for Q3 2025, with a net profit of €219 million, earnings per share of €2.77, and a return on tangible common equity (RoTCE) of 27.8% [1][3] - The company achieved a net profit of €630 million and earnings per share of €7.98 for the first nine months of 2025, reflecting a solid financial position [1][3] - The CET1 ratio stood at 14.1% after accounting for a dividend accrual of €346 million, indicating a robust capital position [2] Financial Performance - Core revenues for Q3 2025 reached €554 million, a 43% increase year-over-year, while year-to-date core revenues totaled €1,636.7 million, up 40% [5] - Net interest income for Q3 was €460 million, up 48% year-over-year, and year-to-date net interest income was €1,363.4 million, an increase of 45% [5] - Operating expenses increased by 58% in Q3 to €200.3 million, with year-to-date operating expenses at €604.6 million, up 59% [5] - The net profit for Q3 was €218.5 million, a 23% increase compared to the previous year, and the profit before tax was €293.5 million, up 23% [5] Shareholder Returns - The company executed a €175 million share buyback in Q3 2025, canceling 1.6 million shares, resulting in 77 million shares outstanding, a reduction of 23% since the IPO in 2017 [2][4] - The liquidity coverage ratio (LCR) was reported at 201%, reflecting a strong liquidity position despite a decrease of 59 basis points [5] Strategic Outlook - BAWAG Group expects to outperform its full-year targets for 2025 and reconfirms its mid-term targets as presented during the Investor Day on March 4, 2025 [3] - The integration of recent acquisitions is progressing well, serving as a catalyst for organizational redesign towards a digital-first banking approach [5]